Xeris Biopharma Holdings, Inc. revenue for the last year amounted to 196.64 M USD, the most of which — 196.64 M USD — came from its highest performing source at the moment, Gvoke, Keveyis and Recorlev, the year earlier bringing 153.36 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Xeris Biopharma Holdings, Inc. 203.07 M USD, and the year before that — 163.91 M USD.